Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
cisplatin
forced diuresis
furosemide
mannitol
non-small cell lung cancer
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
14
12
2019
accepted:
18
06
2020
pubmed:
5
9
2020
medline:
4
2
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
Evidence is lacking on the best standard method for forced diuresis to prevent cisplatin-induced nephrotoxicity. We compared the cisplatin-induced nephrotoxicity prevention effect of furosemide or mannitol in patients with advanced non-small cell lung cancer. Patients with advanced non-small cell lung cancer suitable to receive cisplatin-containing regimen were randomly assigned to receive furosemide or mannitol with appropriate hydration. The primary endpoint was the proportion of ≥ grade 1 serum creatinine elevation in the first cycle. The trial was terminated early with 44 (22 per arm) of the planned 66 patients because of slow accrual. Patients' characteristics were well balanced with median baseline creatinine clearance of 98.0 and 95.1 mL/min in the furosemide and mannitol arms, respectively. In the first cycle, two (9%) and four (18%) patients developed grade 1 creatinine elevation (P = .66), respectively, despite no ≥ grade 2 toxicity. The median times to develop the worst creatinine score were 10 and 8 days, respectively. For all cycles, median times to recover to grade 0 were 56 and 20 days, respectively. The furosemide arm was characterized by relatively high urine output after cisplatin administration (900 vs 550 mL/h), low frequency of unplanned additional hydration (14% vs 32%), and high incidence of hyponatremia (18% and 5%) compared with the mannitol arm. Both arms showed similar progression-free survival and overall survival. The preventive effect of the two forced diuretics on cisplatin-induced nephrotoxicity was not significantly different. However, the two diuretics have some distinct types of clinical presentations.
Substances chimiques
Drug Combinations
0
Mannitol
3OWL53L36A
Furosemide
7LXU5N7ZO5
Cisplatin
Q20Q21Q62J
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-108Subventions
Organisme : Center for Innovative Clinical Medicine, Okayama University Hospital
Informations de copyright
© 2020 John Wiley & Sons Australia, Ltd.
Références
Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852-3859.
Hotta K, Matsuo K. Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer. J Thorac Oncol. 2007;2:96.
Hotta K, Fujiwara Y, Matsuo K, et al. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer. 2007;109:939-948.
Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol. 2004;15:1782-1789.
Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40:293-308.
Hotta K, Takigawa N, Hisamoto-Sato A, et al. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol. 2013;43:1115-1123.
Ninomiya K, Hotta K, Hisamoto-Sato A, et al. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol. 2016;21:81-87.
Hotta K, Ninomiya K, Takigawa N, Tanimoto M, Kiura K. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Jpn J Clin Oncol. 2015;45:603-604.
Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist. 2017;22:609-619.
Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer. 1977;39:1357-1361.
Morgan KP, Snavely AC, Wind LS, et al. Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol. Ann Pharmacother. 2014;48:863-869.
Tiseo M, Martelli O, Mancuso A, et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori. 2007;93:138-144.
Pera MF, Jr, Zook BC, Harder HC. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats. Cancer Res. 1979;39:1269-1278.
Ostrow S, Egorin MJ, Hahn D, et al. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep. 1981;65:73-78.
Santoso JT, Lucci JA, 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52:13-18.
Makimoto G, Ichihara E, Hotta K, et al. Randomized phase II study comparing mannitol with furosemide for the prevention of renal toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: the OLCSG1406 Study Protocol. Acta Med Okayama. 2018;72:319-323.
Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcislo K, Szczylik C. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer. 2008;44:2608-2614.
Furukawa N, Kawaguchi R, Kobayashi H. Use of high-dose cisplatin with aprepitant in an outpatient setting. Eur J Cancer Care. 2012;21:436-441.
Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35:3240-3261.
Horinouchi H, Kubota K, Itani H, et al. Short hydration in chemotherapy containing cisplatin (>/ = 75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol. 2013;43:1105-1109.
Hata A, Katakami N, Masuda Y, et al. Cisplatin administration for outpatients with short hydration of less than four hours. Gan To Kagaku Ryoho. 2012;39:1385-1388.
Korogi Y, Yoshioka H, Kunimasa K, et al. Retrospective analysis of short-hydration cisplatin-based chemotherapy. J Jpn Respir Soc. 2013;2:730-736.
Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69:1375-1381.
Sekine I, Yamada K, Nokihara H, et al. Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity. Cancer Sci. 2007;98:1408-1412.
Sekine I, Kubota K, Tamura Y, et al. Innovator and generic cisplatin formulations: comparison of renal toxicity. Cancer Sci. 2011;102:162-165.
Nagai N, Ogata H. The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats. J Pharm Sci. 1996;85:720-724.
Numico G, Benasso M, Vannozzi MO, et al. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis. Anticancer Res. 1998;18:1313-1318.
Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18:317-323.